MREO vs. ELVN, TRML, TRVI, IMNM, WVE, CVAC, MAZE, ATAI, CALT, and ARDX
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Enliven Therapeutics (ELVN), Tourmaline Bio (TRML), Trevi Therapeutics (TRVI), Immunome (IMNM), WAVE Life Sciences (WVE), CureVac (CVAC), Maze Therapeutics (MAZE), atai Life Sciences (ATAI), Calliditas Therapeutics AB (publ) (CALT), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.
Mereo BioPharma Group vs. Its Competitors
Mereo BioPharma Group (NASDAQ:MREO) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
In the previous week, Enliven Therapeutics had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 6 mentions for Enliven Therapeutics and 3 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.43 beat Enliven Therapeutics' score of 0.16 indicating that Mereo BioPharma Group is being referred to more favorably in the media.
Mereo BioPharma Group has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.
Mereo BioPharma Group has higher revenue and earnings than Enliven Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.
Enliven Therapeutics' return on equity of -29.15% beat Mereo BioPharma Group's return on equity.
Mereo BioPharma Group presently has a consensus target price of $7.40, suggesting a potential upside of 247.42%. Enliven Therapeutics has a consensus target price of $41.20, suggesting a potential upside of 94.43%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Enliven Therapeutics.
62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 5.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Enliven Therapeutics beats Mereo BioPharma Group on 9 of the 15 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
This page (NASDAQ:MREO) was last updated on 10/22/2025 by MarketBeat.com Staff
